Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Aug 10, 2012

NEW YORK (GenomeWeb News) – Dale Levitzke has been appointed vice president of global sales for life sciences at NanoString Technologies. Levitzke joins the company from Illumina, where he was senior director and global sales manager for the company's PCR division.

Previously, he was head of global sales for Helixis, general manager of Corbett Robotics, and core facility manager at the University of Newcastle's Analytical and Biomolecular Research Facility. He holds a BS in molecular biology from La Trobe University Melbourne.

Agendia said this week that Stefan Gluck will serve as chair of its medical advisory board. Gluck is a professor at the Miller School of Medicine at the University of Miami. He spent five years as clinical director of the Braman Family Breast Cancer Institute and had previously served as director of the Southern Alberta Breast Cancer Program at the Tom Baker Cancer Center and as a professor at the University of Calgary.

Accelr8 has named Steve Reichling to be company CFO. Reichling joins Accelr8 from Roche Tissue Diagnostics, where he was GM of its Spring Bioscience antibody R&D and research products subsidiary. He also worked in finance at Ventana Medical Systems and he was a life sciences auditor at Ernst and Young.

Response Biomedical said this week that Bill Adams will take over the CFO position from Richard Canote, who has resigned that title but will remain with the company as a consultant, as of August 13. Adams previously was CFO at CellFor, and before that he held the same job at AnorMed and at Epic Data.

ILS Genomics said this week that Leslie Recio has been appointed as director of its new genomics division, where she will be responsible for the company's scientific pursuits and development, as well as identifying and integrating new technology platforms.

Recio also is division director of ILS' Genetic and Molecular Toxicology Division, and she has over 25 years of experience in toxicological research focused on mutagenesis, toxicogenomics, and regulatory-based genotoxicity assessment.

Response Genetics' stockholders have re-elected the members of its board of directors for one-year terms, including company CEO and Chairman Thomas Bologna; Kick Calhoun; Michael Metzger; Gary Nusbaum; Michael Serruya; Richard van den Broek; and David Wurzer.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.